Article in The Journal of experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
16 authors.
Chehyun Nam *Center for Craniofacial Molecular Biology, Herman Ostrow School of Dentistry, and Norris Comprehensive Cancer Center, University of Southern California , Los Angeles, CA, USA.ORCID 0000-0001-8604-2313
Guowei Huang *Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.ORCID 0000-0002-1425-5237
Yueyuan Zheng *Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.ORCID 0000-0002-5692-8903
Hua ZhaoCenter for Craniofacial Molecular Biology, Herman Ostrow School of Dentistry, and Norris Comprehensive Cancer Center, University of Southern California , Los Angeles, CA, USA.ORCID 0000-0001-7148-547X
Yuhao PanCenter for Craniofacial Molecular Biology, Herman Ostrow School of Dentistry, and Norris Comprehensive Cancer Center, University of Southern California , Los Angeles, CA, USA.ORCID 0009-0003-6676-1531
Boyan HuCenter for Craniofacial Molecular Biology, Herman Ostrow School of Dentistry, and Norris Comprehensive Cancer Center, University of Southern California , Los Angeles, CA, USA.ORCID 0009-0002-1872-9556
Talia WengerCenter for Craniofacial Molecular Biology, Herman Ostrow School of Dentistry, and Norris Comprehensive Cancer Center, University of Southern California , Los Angeles, CA, USA.ORCID 0000-0001-6616-2780
Hieu T VanNational Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health , Bethesda, MD, USA.ORCID 0000-0002-3328-915X
Li-Yan XuInstitute of Oncologic Pathology, Shantou University Medical College , Shantou, China.ORCID 0000-0002-1618-4292
En-Min LiInstitute of Oncologic Pathology, Shantou University Medical College , Shantou, China.ORCID 0000-0001-6375-3614
H Phillip KoefflerDepartment of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Kai GeNational Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health , Bethesda, MD, USA.ORCID 0000-0002-7442-5138
Yali DouDepartment of Medicine, Department of Biochemistry and Molecular Medicine, University of Southern California, Los Angeles, CA, USA.ORCID 0000-0002-4040-1429
Uttam K SinhaDepartment of Otolaryngology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.ORCID 0000-0003-4208-8904
Young Min ParkCenter for Craniofacial Molecular Biology, Herman Ostrow School of Dentistry, and Norris Comprehensive Cancer Center, University of Southern California , Los Angeles, CA, USA.ORCID 0000-0002-7593-8461
De-Chen LinCenter for Craniofacial Molecular Biology, Herman Ostrow School of Dentistry, and Norris Comprehensive Cancer Center, University of Southern California , Los Angeles, CA, USA.ORCID 0000-0002-1951-367X
Funding
USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
Master regulator transcription factors promote esophageal neoplastic evolutionR37CA237022 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI LIN, DE-CHEN · 2020 to 2025
$2.7M
Modeling Pathways of Early Growth Dysregulation at the GEJR01DK135562 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI De-Chen Lin, Stephen J Meltzer · 2024 to 2026
$2.1M
Pharmacological and dietary inhibition of a novel metabolic-epigenetic crosstalk in head and neck cancerR01DE033648 · NIDCR · UNIVERSITY OF SOUTHERN CALIFORNIA · PI De-Chen Lin · 2024 to 2026
$1.5M
Concern Foundation for Cancer ResearchGuangdong Natural Science Foundation 2024A1515013059Ming Hsieh Institute for Research of Engineering-Medicine for CancerNCI NIH HHS P30 CA014089NCI NIH HHS P30CA014089NCI NIH HHS R37 CA237022NIDCR NIH HHS R01 DE033648NIDDK NIH HHS R01 DK135562NIH HHS R37CA237022Ostrow School of Dentistry of USC Faculty Seed GrantWatt Family Endowed Chair for Head and Neck Cancer ResearchWright Foundation
6 · The paper itself
Abstract
Upper aerodigestive squamous cell carcinoma (UASCC) presents significant challenges in clinical management due to its aggressive nature. Here, we elucidate the role of MLL3 mutations as early, clonal genomic events in UASCC tumorigenesis, highlighting their role as foundational drivers of cancer development. Utilizing CRISPR-edited, cross-species organoid modeling, we demonstrate that loss of MLL3 contributes to early squamous neoplastic evolution. Furthermore, we identify an MLL3/GRHL2 protein complex that regulates the UASCC epigenome, particularly impacting immune response pathways. Notably, a novel MLL3/GRHL2-IRF1 axis promotes the expression of Th1 chemokines, enhancing anti-tumor immunity by facilitating T cell infiltration into the tumor microenvironment. Consequently, MLL3 regulates the in vivo efficacy of immune checkpoint blockade (ICB) therapy, corroborated by the strong association between MLL3 expression and human patients' clinical response to ICB therapy. Our work underscores the significance of MLL3 in UASCC pathogenesis and highlights the interplay between MLL3/GRHL2 and immune response pathways as potential therapeutic targets for UASCC treatment.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The MLL3/GRHL2 complex regulates malignant transformation and anti-tumor immunity in squamous cancer. · full record | OpenQuestion